1. Home
  2. ARMP vs GAUZ Comparison

ARMP vs GAUZ Comparison

Compare ARMP & GAUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARMP
  • GAUZ
  • Stock Information
  • Founded
  • ARMP N/A
  • GAUZ 2009
  • Country
  • ARMP United States
  • GAUZ Israel
  • Employees
  • ARMP N/A
  • GAUZ N/A
  • Industry
  • ARMP Biotechnology: Biological Products (No Diagnostic Substances)
  • GAUZ Industrial Machinery/Components
  • Sector
  • ARMP Health Care
  • GAUZ Miscellaneous
  • Exchange
  • ARMP Nasdaq
  • GAUZ Nasdaq
  • Market Cap
  • ARMP 104.3M
  • GAUZ 102.0M
  • IPO Year
  • ARMP N/A
  • GAUZ 2024
  • Fundamental
  • Price
  • ARMP $3.12
  • GAUZ $6.33
  • Analyst Decision
  • ARMP Strong Buy
  • GAUZ Strong Buy
  • Analyst Count
  • ARMP 1
  • GAUZ 3
  • Target Price
  • ARMP $9.00
  • GAUZ $13.67
  • AVG Volume (30 Days)
  • ARMP 7.8K
  • GAUZ 47.1K
  • Earning Date
  • ARMP 11-12-2025
  • GAUZ 11-11-2025
  • Dividend Yield
  • ARMP N/A
  • GAUZ N/A
  • EPS Growth
  • ARMP N/A
  • GAUZ N/A
  • EPS
  • ARMP N/A
  • GAUZ N/A
  • Revenue
  • ARMP $6,868,000.00
  • GAUZ $96,810,000.00
  • Revenue This Year
  • ARMP $8.43
  • GAUZ $22.59
  • Revenue Next Year
  • ARMP N/A
  • GAUZ $41.48
  • P/E Ratio
  • ARMP N/A
  • GAUZ N/A
  • Revenue Growth
  • ARMP 84.67
  • GAUZ 7.87
  • 52 Week Low
  • ARMP $0.90
  • GAUZ $4.54
  • 52 Week High
  • ARMP $3.14
  • GAUZ $13.00
  • Technical
  • Relative Strength Index (RSI)
  • ARMP 62.83
  • GAUZ 57.70
  • Support Level
  • ARMP $2.94
  • GAUZ $5.76
  • Resistance Level
  • ARMP $3.07
  • GAUZ $6.71
  • Average True Range (ATR)
  • ARMP 0.08
  • GAUZ 0.45
  • MACD
  • ARMP -0.01
  • GAUZ 0.07
  • Stochastic Oscillator
  • ARMP 97.96
  • GAUZ 71.64

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

About GAUZ Gauzy Ltd. Ordinary Shares

Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.

Share on Social Networks: